Q Chip
Commercializes innovative sustained-release drug formulations of injectable therapeutics.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD33—49m (Dealroom.co estimates May 2011.)
Company register number 04929486
Cardiff Wales (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | - | <1m | <1m | <1m | <1m |
| % growth | 31 % | (91 %) | - | - | 581 % | 226 % | 21 % |
| EBITDA | (4.2m) | (3.9m) | (4.7m) | (7.1m) | (4.0m) | 23.1m | (2.1m) |
| % EBITDA margin | (1221 %) | (12371 %) | - | (22862 %) | (1902 %) | 3333 % | (252 %) |
| Profit | (3.7m) | (3.8m) | (3.7m) | (5.9m) | (3.6m) | 23.2m | (2.1m) |
| % profit margin | (1078 %) | (12042 %) | - | (18954 %) | (1682 %) | 3354 % | (251 %) |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
€500k | Seed | ||
$570k | Seed | ||
| N/A | £2.0m | Early VC | |
| N/A | £1.0m | Early VC | |
£2.0m | Early VC | ||
$6.0m | Series C | ||
N/A | Acquisition | ||
| Total Funding | CAD18.7m | ||